Biomarker Development to Improve Trials for Type 1 Diabetes



November 18, 2013

  • Share
  • Immunotherapy of type 1 diabetes and other autoimmune disorders faces significant hurdles, because therapeutic efficacy needs to be balanced with acceptable side effects. Since development of disease also exhibits heterogeneity depending on age, environmental and genetic factors, it would be desirable to rationally develop a suitable and practical set of biomarkers, that should be able to segregate responders from non-responders and ideally predict efficacy of immune-based intervention on an individual basis. We have developed panel of biomarkers that are specifically based on novel insight into the pathogenesis of T1D achieved as part of the nPOD (national pancreatic organ donor) consortium. This strategy, its implication and realization in future clinical trials and potential impact on individualized medicine will be discussed.


    Keep up to date with all your favourite videos and channels.

    Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.